An update on the status of endothelin receptor antagonists for hypertension

Bibliography

• DAO HH, MOREAU P: Endothelin receptor antagonists: novel agents for the treatment of hypertension. Exp. Opin. Investig. Drugs (1999) 8:1807–1821.
   PubMedGoogle Scholar
• LUSCHER TF, BARTON M: Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation (2000) 102:2434–2440.
   PubMed Web of Science ®Google Scholar
• BARTON M, KIOWSKI W: The therapeutic potential of endothelin receptor antagonists in cardiovascular disease. Cun: Hypertens. Reports (2001) 3:322–330.
   PubMedGoogle Scholar
• YANAGISAWA M, KURIHARA H, KIMURA S etal.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 332:411-415. ccA landmark manuscript that reported thediscovery of endothelin and many of its biological actions.
   Google Scholar
• XU D, EMOTO N, GIAID A, XXX: ECE-1: a membrane-bound metalloprotease that catalyses the proteolytic activation of big endothelin-1. Cell (1994) 78:473–485.
   PubMed Web of Science ®Google Scholar
• SHIMADA K, TAKAHASHI M, TANZAWA K: Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. j Biol. Chem. (1994) 269:18275–18278.
   PubMed Web of Science ®Google Scholar
• WAGNER 0, CHRIST G, WOJTA J etal.:Polar secretion of endothelin-1 by cultured endothelial cells. j Biol. Chem. (1992) 267:16066–16068.
   Google Scholar
• WARNER TD, MITCHELL JA, DE NUCCI G, VANE JR: Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. Cardiovasc. Pharmacol (1989) 13:S85–S88.
   PubMed Web of Science ®Google Scholar
• SEO B, OEMAR BS, SIEBENMANN R, VON LUDWIG S, LOSCHER TF: Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation (1994) 89:1203–1208.
   PubMed Web of Science ®Google Scholar
• RABELINK TJ, STROES ESG, BANTEN KP, MORRISON P: Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in CV diseases? Cardiovasc. Res. (1998) 39:543–549.
   Google Scholar
• SCHIFFRIN EL, TOUYZ RM: Vascular biology of endothelin. j Cardiovasc. Pharmacol (1998) 32:S2–S13.
   PubMed Web of Science ®Google Scholar
• MIYAUCHI T, MASAKI T: Pathophysiology of endothelin in the cardiovascular system. Ann. Rev Physic] (1999) 61:391–415.
   PubMed Web of Science ®Google Scholar
• DOHI Y, HAHN AWA, BOULANGER CM, BOHLER FR, LOSCHER TF: Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension (1992) 19:131–137.
   PubMed Web of Science ®Google Scholar
• GRAINGER DJ, WITCHELL CM, WEISSBERG PL, METCALFE JC: Mitogens for adult rat aortic vascular smooth muscle cells in serum-free primary culture. Cardiovasc. Res. (1994) 28:1238–1242.
   PubMed Web of Science ®Google Scholar
• CHUA BHL, KREBS CJ, CHUA CC, DIGLIO CA: Endothelin stimulates protein systhesis in smooth muscle cells. Am. Physic] (1992) 262:E412–E416.
   PubMed Web of Science ®Google Scholar
• FUJITANI Y, BERTRAND C: ET-1 cooperates with EGF to induce mitogenesis via a PTX-sensitive pathway in airway smooth muscle cells. Am. j Physic] (1997) 272:C1492–C1498.
   Web of Science ®Google Scholar
• SHARIFI AM, SCHIFFRIN EL: Apoptosis in aorta of deoxycorticosterone acetate-salt hypertensive rats: effect of endothelin receptor antagonism. I Hypertens. (1997) 15:1441–1448.
   PubMed Web of Science ®Google Scholar
• SHICHIRI M, KATO H, MARUMO HIRATA Y: Endothelin-1 as an autocrinei paracrine apoptosis survival factor for endothelial cells. Hypertension (1997) 30:1198–1203.
   PubMed Web of Science ®Google Scholar
• THARAUX PL, CHATZIANTONIOU C, CASSELAS D, FOUASSIER L, ARDAILLOU R, DUSSAULE JC: Vascular endothelin-1 gene expression and synthesis and effects on renal Type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats. Circulation (1999) 99:2185–2191.
   PubMed Web of Science ®Google Scholar
• HOCHER B, GEORGE I, REBSTOCK J et al.: Endothelin system-dependent cardiac remodelling in renovascular hypertension. Hypertension (1999) 33:816–822.
   PubMed Web of Science ®Google Scholar
• GUIDRY C: Extracellular matrix contraction by fibroblasts: peptide promoters and second messengers. Cancer Metastasis Rev (1992) 11:45–54.
   PubMed Web of Science ®Google Scholar
• HOCHER B, THONE-REINEKE C, ROHMEISS P et al.: Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. 1 Chu. Invest. (1997) 99:1380–1389.
   Google Scholar
• •The only report available documenting the type of remodeling occurring in several forms of human hypertension.
   Google Scholar
• HOCHER B, LIEFELDT L, THONE-REINEKE C et al.: Characterisation of the renal phenotype of transgenic rats expressing the human endothelin-2 gene. Hypertension (1996) 28:196–201.
   PubMed Web of Science ®Google Scholar
• RIZZONI D, PORTERI E, CASTELLANO M et al.: Vascular hypertrophy and remodelling in secondary hypertension. Hypertension (1996) 28:785–790.
   PubMed Web of Science ®Google Scholar
• RIZZONI D, PORTERI E, GUEFI D et al.:Cellular hypertrophy in subcutaneous small arteries of patients with renovascular hypertension. Hypertension (2000) 35:931–935.
   PubMed Web of Science ®Google Scholar
• ZOCCALI C, LEONARDIS D, PARLONGO S, MALLAMACI POSTORINO M: Urinary and plasma endothelin-1 in essential hypertension and in hypertension secondary to renoparenchymal disease. Nephrol. Dialysis Trawl. (1995) 10:1320–1323.
   PubMed Web of Science ®Google Scholar
• POCH E, JIMENEZ W, FEU F etal.: Increased plasma endothelin concentration in atherosclerotic renovascular hypertension. Nephron (1995) 71:291–296.
   Google Scholar
• HEAGERTY AM, AALKJAER C, BUND SJ, KORSGAARD N, MULVANY MJ: Small artery structure in hypertension: Dual process of remodelling and growth. Hypertension (1993) 21:391–397.
   PubMed Web of Science ®Google Scholar
• SCHIFFRIN EL, DENG LY, SVENTEK P, DAY R: Enhanced expression of endothelin-1 gene in resitance arteries in severe human essential hypertension. 1 Hypertens. (1997) 15:57–63.
   PubMed Web of Science ®Google Scholar
• PARK JB, SCHIFFRIN EL: ET(A) receptor antagonist prevents blood pressure elevation and vascular remodelling in aldosterone-infused rats. Hypertension (2001) 37:1444–1449.
   PubMed Web of Science ®Google Scholar
• DAO HH, MARTENS FMAC, LARIVIERE R etal.: Transient involvement of endothelin in hypertrophic remodelling of small arteries. I Hypertens. (2001) 19:1801–1812.
   Google Scholar
• •The first report to demonstrate a transient role of ET in vascular remodelling.
   Google Scholar
• MOREAU E D'USCIO LV, TAKASE H, SHAW S, BARTON M, LOSCHER TF: Angiotensin II increases tissue endothelin and induced vascular hypertrophy in vivo: reversal by ETA-receptor antagonist. Circulation (1997) 96:1593–1597.
   Google Scholar
• HERIZI A, BELABBAS H, MIMRAN A, JOVER B: Cardiac and vascular hypertrophy in hypertension due to angiotensin II. Effect of losartan and bosentan. Arch. Mal. Coeur. (2000) 93:983–986.
   PubMedGoogle Scholar
• DAO HH, LEMAY J, DE CHAMPLAIN J, DEBLOIS D, MOREAU P: Norepineprhine-induced aortic hyperplasia and extracellular matrix deposition is endothelin-dependent. I Hypertens. (2001) (In Press).
   Google Scholar
• EHMKE H, FAULHAER J, MUNTER K, KIRCHENGAST M, WIESNER RJ: Chronic ETAreceptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats. Hypertension (1999) 33:954–960.
   PubMed Web of Science ®Google Scholar
• LI JS, KNAFO L, TURGEON A, GARCIA R, SCHIFFRIN EL: Effect of endothelin antagonism on blood pressure and vascular structure in renovascular hypertensive rats. Am. I Physiol. (1996) 40:H88–H93.
   Google Scholar
• BIANCIOTTI LG, DE BOLD AJ: Modulation of cardiac natriuretic peptide gene expression following endothelin type A receptor blockade in renovascular hypertension. Cardiovasc. Res. (2001) 49:808–816.
   PubMed Web of Science ®Google Scholar
• SCHIFFRIN EL, TURGEON A, DENG LY: Effects of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats. Br. I Pharmacol. (1997) 121:935–40.
   PubMed Web of Science ®Google Scholar
• LI J-S, SCHIFFRIN EL: Effect of chronictreatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension (1995) 25:495–500.
   PubMed Web of Science ®Google Scholar
• KARAM H, HEUDES D, BRUVENAL P, GONZALES MF, LOFFLER BM, CLOZEL M et al.: Endothelin antagonism in end-organ damage of spontaneously hypertensive rats. Comparison with angiotensin-converting enzyme inhibition and calcium antagonism. Hypertension (1996) 28:379–385.
   Google Scholar
• BLEZER ELA, NICOLAY K, GOLDSCHMEDING R, JANSEN GH, KOOMANS HA, RABELINK TJ et al.: Early, but not late-onset, endothelin A receptor blockade can modulate hypertension, cerebral oedema and proteinuria in stroke-prone hypertensive rats. Hypertension (1999) 33:137–144.
   PubMed Web of Science ®Google Scholar
• •One of few reports that studied prevention and regression of cardiovascular alterations with an ETRA. In addition, the effect of the drug on mortality was also assessed in a model of hypertension-induced stroke (SHR-SP).
   Google Scholar
• STASCH J-P, HIRTH-DIETRICH C, FROBEL K, WEGNER M: Prolonged endothelin blockade prevents hypertension and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Am. Hypertens. (1995) 8:1128–1134.
   PubMed Web of Science ®Google Scholar
• CHILLON J-M, HEISTAD DD, BAUMBACH GL: Effects of endothelin receptor inhibition on cerebral arterioles in hypertensive rats. Hypertension (1996) 27:794–798.
   PubMed Web of Science ®Google Scholar
• OKADA M, NISHINO M, SAITO M, IKEDA T, UEHARA S, OKADA H et al.: Marked reduction of mortality in salt-loaded Dahl salt-sensitive rats by the new, selective endothelin ETA receptor antagonist, J-105859.1 Hypertens. (2000) 18:1815–1823.
   Google Scholar
• TOUYZ RIVI, TURGEON A, SCHIFFRIN EL: Endothelin-A-receptor blockade improves renal function and doubles the lifespan of stroke-prone spontaneously hypertensive rats. I Cardiovasc. Pharmacol. (2000) 36:S300–S304.
   PubMed Web of Science ®Google Scholar
• •Demonstration of a major effect on survival of SHR-SP with an ETRA without important reduction in arterial pressure.
   Google Scholar
• GARDINER SM, MARCH JE, KEMP PA, BENNETT T: Cardiovascular effects of endothelin-1 and endothelin antagonists in conscious, hypertensive ((mRen-2)27) rats. Br. J. Pharmacol. (2000) 131:1732–1738.
   PubMed Web of Science ®Google Scholar
• ROSSI GP, SACCHETTO A, RIZZONI D et al.: Blockade of angiotensin II Type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms. Arterioscler. Thromb. Vasc. Biol. (2000) 20:949–956.
   PubMed Web of Science ®Google Scholar
• RIZZONI D, PORTERI E, PICCOLI A et al.: The vasoconstriction induced by endothelin-1 is mediated only by ET(A) receptors in mesenteric small resistance arteries of spontaneously hypertensive rats and Wistar Kyoto rats. I Hypertens. (1997) 15:1653–1657.
   PubMed Web of Science ®Google Scholar
• OHUCHI T, KUWAKI T, LING GY et al: Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice. Am. j Physiol. (1999) 276:R1071–R1077.
   PubMed Web of Science ®Google Scholar
• GARIEPY CE, OHUCHI T, WILLIAMS SC, RICHARDSON JA, YANAGISAWA M: Salt-sensitive hypertension in endothelin- B receptor-deficient rats. j Clin. Invest. (2000) 105:925–933.
   PubMed Web of Science ®Google Scholar
• MATSUMURA Y, KURO T, KOBAYASHI Y et al.: Exaggerated vascular and renal pathology in endothelin-B receptor- deficient rats with deoxycorticosterone acetate-salt hypertension. Circulation (2000) 102:2765–2773.
   PubMed Web of Science ®Google Scholar
• CLOZEL M, BREU V: The role of ETB receptors in normotensive and hypertensive rats as revealed by the non-peptide selective ETB receptor antagonist Ro 46-8443. PEGS Lett. (1996) 383:42–45.
   Google Scholar
• POLLOCK DM, POLLOCK JS: Evidence for endothelin involvement in the response to high salt. Am. j Physiol (2001) 281:F144–F150.
   Web of Science ®Google Scholar
• KRUM H, VISKOPER RV, LACOURCIERE Y, BUDDE M, CHARLON V: The effect of an endothelin receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl. I Med. (1998) 338:784–790.
   PubMed Web of Science ®Google Scholar
• ••Demonstration of a major effect on survivalof SHR-SP with an ETRA without important reduction in arterial pressure.
   Google Scholar
• HONING ML, HIJMERING ML, BALLARD DE et al.: Selective ET(A) receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans. I Am. Soc. Nephrol (2000) 11:1498–1504.
   PubMed Web of Science ®Google Scholar
• VERHAAR MC, GRAHN AY, VAN WEERDT AW et al: Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans. Br. j Clin. Pharmacol (2000) 49:562–573.
   PubMed Web of Science ®Google Scholar
• WEBER C, SCHMITT R, BIRNBOECK Het al: Pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist bosentan in healthy human subjects. Clin. Pharmacol Ther. (1996) 60:124–137.
   PubMed Web of Science ®Google Scholar
• HAYNES WG, FERRO CJ, OKANE SOMMERVILLE D, LOMAX CC, WEBB DJ: Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation (1996) 93:1860–1870.
   PubMed Web of Science ®Google Scholar
• PLUMPTON C, FERRO CJ, HAYNES WG, WEBB DJ, DAVENPORT AP: The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br. J. Pharmacol (1996) 119:311–314.
   PubMed Web of Science ®Google Scholar
• TADDEI S, VIRDIS A, GHIADONI L, SUDANO I, NOTARI M, SALVETTI A: Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation (1999) 100: 1680-1683.
   Google Scholar
• •Important finding of enhanced responsiveness to ETRA in essential hypertension.
   Google Scholar
• NAKOV R, PFARR E, EBERLE S: LU135252: an endothelin A receptor antagonist for treatment of hypertension, dose response, efficacy and safety. The HEAT study: Hypertension, Endothelin Antagonist Treatment. Eur. Heart J. (2001) 22 (Abstract supplement) :611.
   Google Scholar
• VERHAAR MC, STRACHAN FE, NEWBY DE et al: Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation (1998) 97:752–756.
   PubMed Web of Science ®Google Scholar
• STRACHAN FE, SPRATT JC, WILKINSON IB, JOHNSTON NR, GRAY GA, WEBB DJ: Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension (1999) 33:581–585.
   PubMed Web of Science ®Google Scholar
• HAYNES WG, FERRO CJ, WEBB DJ: Bosentan in essential hypertension [letter; comment]. N Eng] J. Med. (1998) 339:346–347.
   PubMedGoogle Scholar
• CARDILLO C, KILCOYNE CM, WACLAWIW M, CANNON RO, 3RD, PANZA JA: Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension (1999) 33:753–758.
   PubMed Web of Science ®Google Scholar
• FATTINGER K, FUNK C, PANTZE M, WEBER C, REICHEN J, STIEGER B et al: The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol Ther. (2001) 69:223–231.
   PubMed Web of Science ®Google Scholar
• HURLIMANN D, RUSCHITZKA F, ENSELEIT F et al.: Effects of long-term selective ETA receptor blockade on neurohumoral activation in congestive heart failure. Eur. Heart J (2001) 22 (Abstract supplement):378.
   Google Scholar
• CLOUTHIER DE, HOSODA K, RICHARDSON JA et al: Cranial and cardiac neural crest defects in endothelin-A receptor- deficient mice. Development (1998) 125:813–824.
   PubMed Web of Science ®Google Scholar
• ROTHERMUND L, PINTO YM, HOCHER B et al.: Cardiac endothelin system impairs left ventricular function in renin- dependent hypertension via decreased sarcoplasmic reticulum Ca(2+) uptake. Circulation (2000) 102:1582–1588.
   PubMed Web of Science ®Google Scholar
• WENZEL RR, RUTHEMANN J, BRUCK H, SCHAFERS RF, MICHEL MC, PHILIPP T: Endothelin-A receptor antagonist inhibits angiotensin II and noradrenaline in man. Br. j Clin. Pharmacol (2001) 52:151–157.
   PubMed Web of Science ®Google Scholar
• BOHLENDER J, GERBAULET S, KRAMER J, GROSS M, KIRCHENGAST M, DIETZ R: Synergistic effects of AT(1) and ET(A) receptor blockade in a transgenic, angiotensin II-dependent, rat model. Hypertension (2000) 35:992–997.
   PubMed Web of Science ®Google Scholar
• •Demonstration of synergy between ATI and ETRA for blood pressure control. Single drugs were effective to prevent end-organ damage, suggesting that it is achieved with sub antihypertensive doses.
   Google Scholar
• MOREAU E RABELINK TJ: Endothelin and its antagonists in hypertension: can we foresee the future? Cun: Hyperteris. Reports (1999) 1:79–78.
   Google Scholar
• ERGUL S, PARISH DC, PUETTE D, ERGUL A: Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension (1996) 28:652–655.
   PubMed Web of Science ®Google Scholar
• ••This manuscript presents an importantheterogeneity of endothelin levels in hypertensive patients. The results suggest that African-Americans may benefit more importantly than Caucasians from ETRA.
   Google Scholar
• WEIR MR: Salt intake and hypertensive renal injury in African Americans. Am. Hyperteris. (1995) 8:635–644.
   PubMed Web of Science ®Google Scholar
• SEVER P: The heterogeneity of hypertension: why doesn't every patient respond to every antihypertensive drug? Cardiovasc. Pharmacol (1998) 31\(Suppl. 2):S1–S4.
   Google Scholar
• COCA A: Actual blood pressure control: are we doing things right? J. Hyperteris. (1998) 16:S45–51.
   Google Scholar
• CLOZEL M, QIU C, OSTERWALDER R et al: Effects of nonpeptide endothelin receptor antagonists in rats with reduced renal mass. j Cardiovasc. Pharinacol (1999) 33:611–618.
   PubMed Web of Science ®Google Scholar
• MOREAU P, TAKASE H, KONG CF, SHAW S, LOSCHER TF: Blood pressure and vascular effects of endothelin blockade in chronic nitric oxide-deficient hypertension. Hypertension (1997) 29:763–769.
   PubMed Web of Science ®Google Scholar
• LI JS, LARIVIERE R, SCHIFFRIN EL: Effect of a nonselective endothelin antagonist on vascular remodelling in deoxycorticosterone acetate-salt hypertensive rats: Evidence for a role of endothelin in vascular hypertrophy. Hypertension (1994) 24:183–188.
   PubMed Web of Science ®Google Scholar
• ••First report showing an impressive effect ofETRA on small artery hypertrophy, despite modest antihypertensive efficacy, opening the field.
   Google Scholar
• KARAM H, HEUDES D, HESS P, GONZALES MF, LOFFLER BM, CLOZEL M et al.: Respective role of humoral factors and blood pressure in cardiac remodelling of DOCA hypertensive rats. Cardiovasc. Res. (1996) 31:287–295.
   PubMed Web of Science ®Google Scholar
• POLLOCK DM, DEREBAIL VK, YAMAMOTO T, POLLOCK JS: Combined effects of AT(1) and ET(A) receptor antagonists, candesartan, and A-127722 in DOCA-salt hypertensive rats. Gen. Phannac. (2000) 34:337–342.
   PubMedGoogle Scholar
• MATSUMURA Y, HASHIMOTO N, TAIRA S et al.: Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats. Hypertension (1999) 33:759–765.
   PubMed Web of Science ®Google Scholar
• HERIZI A, JOVER B, BOURIQUET N, MIMRAN A: Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension (1998) 31:10–14.
   PubMed Web of Science ®Google Scholar
• SHARIFI AM, HE G, TOUYZ RIVI, SCHIFFRIN EL: Vascular endothelin-1 expression and effect of an endothelin ETA antagonist on structure and function of small arteries from stroke- prone spontaneously hypertensive rats. I Cardiovasc. Pharinacol (1998) 31:S309–S312.
   PubMed Web of Science ®Google Scholar
• D'USCIO L, BARTON M, SHAW S, MOREAU E LOSCHER TF: Structure and function of small arteries in salt-induced hypertension: Effects of chronic ETA-receptor blockade. Hypertension (1997) 30:905–911.
   PubMed Web of Science ®Google Scholar
• KASSAB S, MILLER MT, NOVAK J, RECKELHOFF J, CLOWER B, GRANGER JP: Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertension (1998) 31:397–402.
   PubMed Web of Science ®Google Scholar
• BARTON M, D'USCIO LV, SHAW S, MEYER P, MOREAU P, LOSCHER TF: ETA-receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension (1998) 31:499–504.
   PubMed Web of Science ®Google Scholar
• SVENTEK P, TURGEON A, SCHIFFRIN EL: Vascular endothelin-1 gene expression and effect on blood pressure of chronic ETA endothelin receptor antagonism after nitric oxide synthase inhibition with L-NAME in normal rats. Circulation (1997) 95:240–244.
   PubMed Web of Science ®Google Scholar
• FORTEPIANI LA, JAN VIER JJ, ORTIZMC, ATUCHA NM, GARCIA-ESTAN J: Effect of endothelin blockade on pressure natriuresis in nitric oxide-deficient hypertensive rats. j Hyperteris. (1999) 17:287–291.
   PubMed Web of Science ®Google Scholar